| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
,
*
Department of Medicine, University of Western Ontario, London, Ontario,
Canada
Department of Epidemiology, University of Western Ontario, London,
Ontario, Canada
Department of Biostatistics, University of Western Ontario, London,
Ontario, Canada
§
Department of Medicine, University of Michigan, Ann Arbor,
Michigan
||
VA Medical Center, Ann Arbor, Michigan
¶
Epidemiology Program Division of Kidney, Urological and Hematologic
Diseases, National Institute of Diabetes and Digestive and Kidney Diseases,
Bethesda, Maryland
Correspondence to Dr. Louise M. Moist, London Health Sciences Center, SSC Campus, 375 South Street, London, Ontario, Canada N6A 4G5. Phone: 519-667-6525; Fax: 519-667-6758; E-mail: louise.moist{at}lhsc.on.ca
Abstract. Residual renal function (RRF) in end-stage renal disease is clinically important as it contributes to adequacy of dialysis, quality of life, and mortality. This study was conducted to determine the predictors of RRF loss in a national random sample of patients initiating hemodialysis and peritoneal dialysis. The study controlled for baseline variables and included major predictors. The end point was loss of RRF, defined as a urine volume <200 ml/24 h at approximately 1 yr of follow-up. The adjusted odds ratios (AOR) and P values associated with each of the demographic, clinical, laboratory, and treatment parameters were estimated using an "adjusted" univariate analysis. Significant variables (P < 0.05) were included in a multivariate logistic regression model. Predictors of RRF loss were female gender (AOR = 1.45; P < 0.001), non-white race (AOR = 1.57; P = <0.001), prior history of diabetes (AOR = 1.82; P = 0.006), prior history of congestive heart failure (AOR = 1.32; P = 0.03), and time to follow-up (AOR = 1.06 per month; P = 0.03). Patients treated with peritoneal dialysis had a 65% lower risk of RRF loss than those on hemodialysis (AOR = 0.35; P < 0.001). Higher serum calcium (AOR = 0.81 per mg/dl; P = 0.05), use of an angiotensin-converting enzyme inhibitor (AOR = 0.68; P < 0.001), and use of a calcium channel blocker (AOR = 0.77; P = 0.01) were independently associated with decreased risk of RRF loss. The observations of demographic groups at risk and potentially modifiable factors and therapies have generated testable hypotheses regarding therapies that may preserve RRF among end-stage renal disease patients.
This article has been cited by other articles:
![]() |
S. P. McDonald, M. R. Marshall, D. W. Johnson, and K. R. Polkinghorne Relationship between Dialysis Modality and Mortality J. Am. Soc. Nephrol., January 1, 2009; 20(1): 155 - 163. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ledebo and C. Ronco The best dialysis therapy? Results from an international survey among nephrology professionals NDT Plus, December 1, 2008; 1(6): 403 - 408. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Breborowicz, K. Pawlaczyk, A. Polubinska, K. Gorna, A. Wieslander, O. Carlsson, P. Tam, and G. Wu Effect of peritoneal dialysis on renal morphology and function Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3539 - 3544. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Dittrich, H. Puttinger, M. Schillinger, I. Lang, T. Stefenelli, W. H. Horl, and A. Vychytil Effect of radio contrast media on residual renal function in peritoneal dialysis patients--a prospective study Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1334 - 1339. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. T. Bloomgarden The European Association for the Study of Diabetes Diabetes Care, May 1, 2005; 28(5): 1250 - 1257. [Full Text] [PDF] |
||||
![]() |
J. M. Bargman and T. A. Golper The importance of residual renal function for patients on dialysis Nephrol. Dial. Transplant., April 1, 2005; 20(4): 671 - 673. [Full Text] [PDF] |
||||
![]() |
A. Goldfarb-Rumyantzev, J. F. Hurdle, J. Scandling, Z. Wang, B. Baird, L. Barenbaum, and A. K. Cheung Duration of end-stage renal disease and kidney transplant outcome Nephrol. Dial. Transplant., January 1, 2005; 20(1): 167 - 175. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Abbott, F. C. Trespalacios, L. Y. Agodoa, A. J. Taylor, and G. L. Bakris {beta}-Blocker Use in Long-term Dialysis Patients: Association With Hospitalized Heart Failure and Mortality Arch Intern Med, December 13, 2004; 164(22): 2465 - 2471. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Heaf Underutilization of Peritoneal Dialysis JAMA, February 11, 2004; 291(6): 740 - 742. [Full Text] [PDF] |
||||
![]() |
H. C. Rayner, R. L. Pisoni, J. Bommer, B. Canaud, E. Hecking, F. Locatelli, L. Piera, J. L. Bragg-Gresham, H. I. Feldman, D. A. Goodkin, et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS) Nephrol. Dial. Transplant., January 1, 2004; 19(1): 108 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K.-T. Li, K.-M. Chow, T. Y.-H. Wong, C.-B. Leung, and C.-C. Szeto Effects of an Angiotensin-Converting Enzyme Inhibitor on Residual Renal Function in Patients Receiving Peritoneal Dialysis: A Randomized, Controlled Study Ann Intern Med, July 15, 2003; 139(2): 105 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Schiffl, S. M. Lang, and R. Fischer Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1814 - 1818. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Davies, L. Phillips, P. F. Naish, and G. I. Russell Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival Nephrol. Dial. Transplant., June 1, 2002; 17(6): 1085 - 1092. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J Davies Review: The epidemic of diabetic renal disease -- the practical challenges for renal replacement programmes The British Journal of Diabetes & Vascular Disease, March 1, 2002; 2(2): 86 - 89. [Abstract] [PDF] |
||||
![]() |
J. G. Heaf, H. Lokkegaard, and M. Madsen Initial survival advantage of peritoneal dialysis relative to haemodialysis Nephrol. Dial. Transplant., January 1, 2002; 17(1): 112 - 117. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Gokal Peritoneal Dialysis in the 21st Century: An Analysis of Current Problems and Future Developments J. Am. Soc. Nephrol., January 1, 2002; 13(90001): S104 - 115. [Full Text] [PDF] |
||||
![]() |
L. Piillips, S. J. Davies, and E. White Health-related quality of life assessment in end-stage renal failure Journal of Research in Nursing, May 1, 2001; 6(3): 658 - 670. [Abstract] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673